- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00641511
Pharmacogenetic Clinical Trial of Nepicastat for Post Traumatic Stress Disorder (PTSD)
Pharmacogenetic Clinical Trial of Nepicastat for PTSD
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The primary treatment objective is to assess the global efficacy of nepicastat in the treatment of hyper-arousal in Post Traumatic Stress Disorder (PTSD) in conflict or combat zone experienced veterans, in comparison to placebo. The secondary treatment objectives are to assess the ability of nepicastat to induce PTSD remission; treat PTSD and other PTSD symptom clusters and improve quality of life and overall functioning. A medical safety objective is to assess the tolerability and side effects of nepicastat in the treatment of PTSD in veterans who served in conflict zones at least one time between 1990 -2008 [includes Operation Iraqi Freedom/Operation Enduring Freedom (OIF/OEF), Afghanistan, Gulf War, etc .
This is a 6-week study with the long-term objective is to define the best approach to treating PTSD and enhancing the quality of life in patients. Results from this pilot study will assist clinicians in treating active military service members or veterans with PTSD by developing new treatment algorithms for future larger studies.
Study Type
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Alabama
-
Tuscaloosa, Alabama, United States, 35404
- Tuscaloosa VAMC
-
-
South Carolina
-
Charleston, South Carolina, United States, 29401
- Ralph H. Johnson VA Medical Center
-
-
Texas
-
Houston, Texas, United States, 77030
- Michael E. DeBakey VAMC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed informed consent
- Patient understands the risks and benefits and agrees to visit frequency and procedures
- Male or female
- Any race or ethnic origin
- Served in conflict zones at least one time between 1990 -2008 [includes Operation Iraqi Freedom/Operation Enduring Freedom (OIF/OEF), Afghanistan, Gulf War, etc]
- Currently Active Duty, National Guard, Reservist, Veteran, and/or Retired Military
- DSM-IV Diagnosis of Post-Traumatic Stress Disorder (PTSD)
- No substance use disorders (except for nicotine and caffeine) in the previous 2 months
- Free of psychotropic medication for 2 weeks prior to randomization (a low dose sedative hypnotic is allowed for severe insomnia if used sparingly)
- Physical and laboratory panel are within normal limits or not clinically significant
- Women of childbearing potential must be using medically-approved methods of birth control
- 18 to 65 years of age
Exclusion Criteria:
- Lifetime history of bipolar I, schizophrenia, schizoaffective or cognitive disorders
- Actively considering plans of suicide or homicide
- Psychotic symptoms that in the investigator's opinion impair the patient's ability to give informed consent or make it unsafe for patient to be maintained without a neuroleptic
- Unstable general medical conditions or a contraindication to the use of nepicastat
- Intolerable side effects or allergic reaction to nepicastat
- Women planning to become pregnant or breastfeed during the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1 (Medication arm - SYN117 aka Nepicastat)
Veterans will be receiving the study medication Nepicastat initiated with a 3-day loading phase of 40 mg on day 1, 80 mg on day 2 and 120 mg on day 3 (orally) and be continued at 120 mg once daily; During the 8 weeks (weeks: 7-14) extension phase, those from both treatment groups of the RCT phase will start open-label, active Nepicastat (i.e.
no chance of placebo) treatment and be followed for an additional 8 weeks.
Those who have a prior defined positive clinical response to the study medication, Nepicastat, will be continued on open label Nepicastat at 120mg once daily, in order to assess further improvement and safety; those who do not have a positive clinical response during the 6 weeks RCT will be offered the addition of the standard first-line PTSD pharmacotherapy, Paroxetine.
Paroxetine is an allowed concomitant medication (i.e.
"rescue medication") and is not considered a research medication or subject of a research question during the 8 weeks extension phase.
|
120 mg per day
Other Names:
|
Placebo Comparator: 2 (Placebo arm)
During the 6 weeks ( weeks: 1-6) double- blind, randomized clinical trial (RCT) phase, the veterans who have been randomized to the placebo treatment group will be receiving placebo pills.
During the 8 weeks (weeks: 7-14) extension phase, all veterans from both treatment groups of the RCT phase will start open-label, active Nepicastat (i.e.
no chance of placebo) treatment and be followed by the study team for an additional 8 weeks.
The veterans on the placebo during the RCT will receive the study medication at end of the study week 6, the medication will be initiated with a 3-day loading phase of 40 mg on day 1, 80 mg on day 2 and 120 mg on day 3 (orally) and be continued at 120 mg once daily for 8 weeks until the end of the study.
|
once per day placebo capsules
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in CAPS(D) hyperarousal scores as compared to placebo
Time Frame: 6 weeks
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in Structured Interview of Posttraumatic Stress Disorder (SIP) as compared to placebo
Time Frame: 6 weeeks
|
6 weeeks
|
Change from baseline in Montgomery Asberg Depression Rating Scale (MADRS)as compared to placebo
Time Frame: 6 weeks
|
6 weeks
|
Clinicians global impression of Severity and Improvement
Time Frame: 6 weeks
|
6 weeks
|
Quality of life assessment as measured by the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q).
Time Frame: 6 weeks
|
6 weeks
|
Change from baseline in Davidson Trauma Scale (DTS) as compared to placebo
Time Frame: 6 weeks
|
6 weeks
|
Change from baseline in Sheehan Disability Scale as compared to placebo
Time Frame: 6 weeks
|
6 weeks
|
Change from baseline in Clinician Administered PTSD Scale- Symptom (CAPS-SX) as compared to placebo
Time Frame: 6 weeks
|
6 weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Thomas Kosten, MD, Baylor College of Medicine, and DeBakey VAMC
- Study Director: Lori Davis, MD, Tuscaloosa VAMC
- Principal Investigator: Mark Hamner, MD, Ralph H Johnson VAMC
- Principal Investigator: David P. Graham, MD, Michael E. DeBakey VA Medical Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- H22601
- Inv117-Kosten-CL01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Post Traumatic Stress Disorder (PTSD)
-
Dokuz Eylul UniversityNot yet recruitingPost-Traumatic Stress Disorder (PTSD)
-
The University of Texas at ArlingtonUniversity of Texas at AustinTerminatedPost-traumatic Stress Disorder (PTSD)United States
-
VA Office of Research and DevelopmentNot yet recruitingPost-Traumatic Stress Disorder (PTSD)United States
-
Nepalese Psychological AssociationUnknownPost-traumatic Stress Disorder (PTSD)Nepal
-
NYU Langone HealthYale UniversityTerminatedPost-traumatic Stress Disorder (PTSD)United States
-
Tel-Aviv Sourasky Medical CenterBeth Israel Deaconess Medical Center; Tel Aviv UniversityUnknownPost-traumatic Stress Disorder (PTSD)Israel
-
NYU Langone HealthCompleted
-
Otsuka Pharmaceutical Development & Commercialization...Iqvia Pty LtdTerminatedPost-traumatic Stress Disorder (PTSD)United States
-
VA Office of Research and DevelopmentNot yet recruitingPost-traumatic Stress Disorder (PTSD) | Self-directed ViolenceUnited States
-
Insamlingsstiftelsen Wonsa, World of No Sexual...Karolinska InstitutetCompleted
Clinical Trials on SYN117 (nepicastat)
-
Jiangsu Yahong Meditech Co., Ltd aka AsierisRecruitingUlcerative ColitisUnited States
-
Tuscaloosa Research & Education Advancement CorporationBaylor College of Medicine; James J. Peters Veterans Affairs Medical Center; Acorda... and other collaboratorsCompletedPosttraumatic Stress DisorderUnited States
-
Biotie Therapies Inc.National Institute on Drug Abuse (NIDA)CompletedCocaine DependenceUnited States
-
National Institute on Drug Abuse (NIDA)Completed